IDSE News Staff
The FDA Antimicrobial Drugs Advisory Committee voted in favor of plazomicin (Achaogen) for complicated urinary tract infections, but said more data were needed before it could recommend its approval for bloodstream infections (BSIs).
The FDA asked advice on two questions about these indications. In a 15-0 vote, the committee said Achaogen provided substantial evidence of the safety and effectiveness of plazomicin for the treatment of complicated urinary tract infections (cUTIs),